Patients at risk for development of posttransplant lymphoproliferative disorder: Plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction

被引:153
作者
Wagner, HJ
Wessel, M
Jabs, W
Smets, F
Fischer, L
Offner, G
Bucsky, P
机构
[1] Med Univ Lubeck, Dept Pediat, D-23538 Lubeck, Germany
[2] Med Univ Lubeck, Dept Internal Med, D-23538 Lubeck, Germany
[3] Hannover Med Sch, Dept Pediat, D-3000 Hannover, Germany
[4] Catholic Univ Louvain, Dept Pediat, Brussels, Belgium
关键词
D O I
10.1097/00007890-200109270-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Early diagnosis of Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder (PTLD) is required to detect a stage of disease that is more likely to respond to treatment. Elevated levels of EBV DNA were found in peripheral blood of patients at the onset of PTLD. Methods. To compare plasma and peripheral blood mononuclear cells (PBMCs) as material for real-time quantitative polymerase chain reaction (RQ-PCR) measurement of Epstein-Barr viral load, we used two sets of primers and probes specific for the BAM HI-K or RAM HI-W region of the EBV genome. Results. Patients with PTLD had a median viral load of 19,200 EBV genomes/mug DNA (n=9) or 3,225 EBV genomes/100 mul plasma (n=5), being significantly higher compared with immunosuppressed patients with primary (n=9) or reactivated (n=20) EBV infection or immunosuppressed patients without serological signs of active EBV infection (n=67) (P <0.001). Hence, a value of greater than 5,000 EBV genomes/mug PBMC DNA was considered as a diagnostic parameter for PTLD with a sensitivity and specificity of 1.00 or 0.89, respectively. When plasma was analyzed, however, a value of greater than 1,000 EBV genomes/100 ttl plasma had both a sensitivity and specificity of 1.00 for the diagnosis of PTLD. During remission of PTLD, viral load was more effectively cleared in plasma compared with PBMCs. In plasma of nonimmunosuppressed individuals, even a qualitative detection of EBV-related sequences was sensitive and specific for the diagnosis of primary EBV infection, whereas for analysis of PBMC DNA a quantitative parameter had to be considered to differentiate healthy individuals (< 100 EBV genomes/mug PBMC DNA) from patients with primary EBV infection (> 100 EBV genomes/mug PBMC DNA). Conclusion. Although both PBMCs and plasma were useful as material for EBV-specific RQ-PCR in immunosuppressed patients and nonimmunosuppressed individuals, the specificity of analysis seemed to be higher if plasma was taken for analysis.
引用
收藏
页码:1012 / 1019
页数:8
相关论文
共 42 条
  • [1] Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients
    Anker, P
    Mulcahy, H
    Chen, XQ
    Stroun, M
    [J]. CANCER AND METASTASIS REVIEWS, 1999, 18 (01) : 65 - 73
  • [2] High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders
    Baldanti, F
    Grossi, P
    Furione, M
    Simoncini, L
    Sarasini, A
    Comoli, P
    Maccario, R
    Fiocchi, R
    Gerna, G
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (02) : 613 - 619
  • [3] Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
    Benkerrou, M
    Jais, JP
    Leblond, V
    Durandy, A
    Sutton, L
    Bordigoni, P
    Garnier, JL
    Le Bidois, J
    Le Deist, F
    Blanche, S
    Fischer, A
    [J]. BLOOD, 1998, 92 (09) : 3137 - 3147
  • [4] Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation
    Birkeland, SA
    Bendtzen, K
    Moller, B
    Hamilton-Dutoit, S
    Andersen, HK
    [J]. TRANSPLANTATION, 1999, 67 (06) : 876 - 881
  • [5] Association of interleukin-10 with rejection-sparing effect in septic kidney transplant recipients
    Burke, GW
    Ciancio, G
    Cirocco, R
    Markou, M
    Coker, D
    Roth, D
    Nery, J
    Esquenazi, V
    Miller, J
    [J]. TRANSPLANTATION, 1996, 61 (07) : 1114 - 1116
  • [6] LONG INTERNAL DIRECT REPEAT IN EPSTEIN-BARR VIRUS-DNA
    CHEUNG, A
    KIEFF, E
    [J]. JOURNAL OF VIROLOGY, 1982, 44 (01) : 286 - 294
  • [7] Clementi M, 2000, J CLIN MICROBIOL, V38, P2030
  • [8] PRODUCTION BY EBV INFECTION OF AN EBNA-POSITIVE SUBLINE FROM AN EBNA-NEGATIVE HUMAN LYMPHOMA CELL LINE WITHOUT DETECTABLE EBV DNA
    CLEMENTS, GB
    KLEIN, G
    POVEY, S
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1975, 16 (01) : 125 - 133
  • [9] Conti F, 1998, LAB INVEST, V78, P1281
  • [10] Gallagher A, 1999, INT J CANCER, V84, P442, DOI 10.1002/(SICI)1097-0215(19990820)84:4<442::AID-IJC20>3.3.CO